MajesTEC-10
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1928
- NCT Identifier
- NCT06425991
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.